Kodiak Sciences Inc. (KOD) Financial Ratios
9 years of historical data (2016–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
15.28
↑+877% vs avg
5yr avg: 1.56
30Y Low0.6·High3.5
ROE
↓
-84.7%
↑-53% vs avg
5yr avg: -55.4%
30Y Low-458%·High-22%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
KOD Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Kodiak Sciences Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.3B | $523M | $159M | $374M | $878M | $1.3B | $545M | $51M | — | — |
| Enterprise Value | $2.2B | $425M | $55M | $371M | $327M | $477M | $335M | $-37317116 | — | — |
| P/E Ratio → | -13.04 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 15.28 | 3.48 | 0.60 | 0.86 | 1.32 | 1.56 | 1.58 | 0.59 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
KOD EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
KOD Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -84.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -84.7% | -84.7% | -74.2% | -60.7% | -35.0% | -22.1% | -21.9% | -458.1% | — | — |
| ROA | -43.2% | -43.2% | -45.5% | -42.5% | -27.1% | -18.7% | -21.0% | -86.9% | -363.8% | -141.4% |
| ROIC | -130.7% | -130.7% | -69.9% | -93.9% | -379.7% | -157.8% | -55.0% | — | — | — |
| ROCE | -50.0% | -50.0% | -52.7% | -47.0% | -28.5% | -19.7% | -22.6% | -64.8% | -1382.5% | -178.5% |
KOD Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $168M exceeds total debt of $70M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.47 | 0.47 | 0.68 | 0.43 | 0.27 | 0.09 | 0.01 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.65 | -0.39 | -0.01 | -0.83 | -1.01 | -0.61 | -1.02 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -21332.38 | -18965.50 | -12138.68 | -5440.28 | -6148.75 | -4.78 | -21.54 | -2858.50 |
Net cash position: cash ($168M) exceeds total debt ($70M)
KOD Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Kodiak Sciences Inc.'s current ratio of 6.72x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 9.26x to 6.72x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.72 | 6.72 | 6.93 | 9.26 | 11.36 | 30.93 | 28.97 | 18.74 | 0.17 | 4.06 |
| Quick Ratio | 6.72 | 6.72 | 6.93 | 9.26 | 11.36 | 30.93 | 28.97 | 18.74 | 0.17 | 4.06 |
| Cash Ratio | 6.57 | 6.57 | 6.84 | 9.12 | 11.31 | 30.84 | 28.73 | 18.29 | 0.15 | 3.84 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — |
KOD Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Kodiak Sciences Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $53M | $52M | $52M | $52M | $46M | $38M | $36M | $27M | $7M |
Peer Comparison
Compare KOD with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 KODYou | $2B | -13.0 | — | — | — | — | -84.7% | -130.7% | — |
 ADVM | $96M | -0.7 | — | — | 100.0% | -13915.9% | -189.8% | -124.2% | — |
 OCUL | $2B | -6.8 | — | — | 87.3% | -521.0% | -54.9% | — | — |
 REGN | $74B | 17.1 | 17.8 | 18.1 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 RGNX | $527M | -2.3 | — | — | 59.7% | -280.0% | -79.5% | -53.8% | — |
 GMAB | $17B | 17.6 | 15.4 | 14.5 | 91.7% | 33.6% | 4.5% | 5.0% | 4.1 |
 ABBV | $358B | 85.5 | 15.0 | 20.1 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 NVO | $203B | 12.7 | 9.4 | 44.7 | 81.0% | 41.3% | 60.7% | 36.2% | 0.9 |
 ILMN | $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 TMO | $176B | 26.8 | 19.0 | 28.0 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 CRL | $9B | -62.5 | 13.0 | 17.3 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
See KOD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KOD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KOD vs ADVM
Side-by-side business, growth, and profitability comparison vs Adverum Biotechnologies, Inc..
Start ComparisonKOD — Frequently Asked Questions
Quick answers to the most common questions about buying KOD stock.
What is Kodiak Sciences Inc.'s P/E ratio?
Kodiak Sciences Inc.'s current P/E ratio is -13.0x. This places it at the 50th percentile of its historical range.
What is Kodiak Sciences Inc.'s ROE?
Kodiak Sciences Inc.'s return on equity (ROE) is -84.7%. The historical average is -108.1%.
Is KOD stock overvalued?
Based on historical data, Kodiak Sciences Inc. is trading at a P/E of -13.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.